NZ514696A - IL-8 receptor antagonists - Google Patents

IL-8 receptor antagonists

Info

Publication number
NZ514696A
NZ514696A NZ514696A NZ51469600A NZ514696A NZ 514696 A NZ514696 A NZ 514696A NZ 514696 A NZ514696 A NZ 514696A NZ 51469600 A NZ51469600 A NZ 51469600A NZ 514696 A NZ514696 A NZ 514696A
Authority
NZ
New Zealand
Prior art keywords
receptor antagonists
chemokine
interleukin
formula
treatment
Prior art date
Application number
NZ514696A
Inventor
Gregory Martin Benson
Melvin Clarence Rutledge
Katherine L Iddowson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Priority to NZ521057A priority Critical patent/NZ521057A/en
Publication of NZ514696A publication Critical patent/NZ514696A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention relates to novel compounds of Formula (I), and pharmaceutical compositions thereof, and methods of treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
NZ514696A 1999-06-16 2000-06-15 IL-8 receptor antagonists NZ514696A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ521057A NZ521057A (en) 1999-06-16 2000-06-15 IL-8 receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14002499P 1999-06-16 1999-06-16
PCT/US2000/016506 WO2000076501A1 (en) 1999-06-16 2000-06-15 Il-8 receptor antagonists

Publications (1)

Publication Number Publication Date
NZ514696A true NZ514696A (en) 2004-03-26

Family

ID=22489379

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ514696A NZ514696A (en) 1999-06-16 2000-06-15 IL-8 receptor antagonists

Country Status (19)

Country Link
EP (1) EP1185265A4 (en)
JP (1) JP2003501463A (en)
KR (1) KR20020015347A (en)
CN (1) CN1356899A (en)
AR (1) AR024350A1 (en)
AU (1) AU766235B2 (en)
BR (1) BR0011122A (en)
CA (1) CA2377386A1 (en)
CO (1) CO5190696A1 (en)
CZ (1) CZ20014472A3 (en)
HU (1) HUP0201582A3 (en)
IL (1) IL145762A0 (en)
MX (1) MXPA01013005A (en)
NO (1) NO20016052D0 (en)
NZ (1) NZ514696A (en)
PL (1) PL352213A1 (en)
TR (1) TR200103638T2 (en)
WO (1) WO2000076501A1 (en)
ZA (1) ZA200109480B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05003867A (en) 2002-10-09 2005-11-23 Schering Corp Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands.
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10334309A1 (en) * 2003-07-28 2005-03-03 Aventis Pharma Deutschland Gmbh Substituted thiazole-Benzoisothiazoldioxidderivate, processes for their preparation and their use
WO2005021531A1 (en) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl c-kit inhibitors
BRPI0413785A (en) 2003-08-21 2006-11-07 Osi Pharm Inc compound, composition, and method of treating hyperproliferative disorder
US7442709B2 (en) 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
CN1918138B (en) 2003-12-19 2011-05-04 先灵公司 Thiadiazoles as cxc- and cc- chemokine receptor ligands
US7582673B2 (en) 2004-10-21 2009-09-01 High Point Pharmaceuticals, Llc Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
EP1831206B1 (en) 2004-12-01 2011-08-24 OSI Pharmaceuticals, Inc. N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
CN102066372B (en) 2009-08-24 2014-09-17 苏州爱斯鹏药物研发有限责任公司 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors
EP2377850A1 (en) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
CN102060780B (en) 2010-12-27 2014-11-05 雅本化学股份有限公司 Preparation method of 2-(N-substituted).-aminobenzimidazole derivative
CN111116502A (en) * 2018-10-30 2020-05-08 中国石油化工股份有限公司 One-step method for synthesizing benzotriazole

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
KR20000070368A (en) * 1997-01-23 2000-11-25 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 IL-8 Receptor Antagonists

Also Published As

Publication number Publication date
AR024350A1 (en) 2002-10-02
AU766235B2 (en) 2003-10-09
TR200103638T2 (en) 2002-04-22
CZ20014472A3 (en) 2002-06-12
MXPA01013005A (en) 2002-07-02
JP2003501463A (en) 2003-01-14
KR20020015347A (en) 2002-02-27
NO20016052L (en) 2001-12-11
EP1185265A4 (en) 2004-02-04
HUP0201582A2 (en) 2002-12-28
NO20016052D0 (en) 2001-12-11
AU5616100A (en) 2001-01-02
CA2377386A1 (en) 2000-12-21
CN1356899A (en) 2002-07-03
EP1185265A1 (en) 2002-03-13
CO5190696A1 (en) 2002-08-29
WO2000076501A1 (en) 2000-12-21
HUP0201582A3 (en) 2003-02-28
ZA200109480B (en) 2002-11-18
PL352213A1 (en) 2003-08-11
BR0011122A (en) 2002-02-26
IL145762A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
TR199901710T2 (en) IL-8 receptor antagonists.
EA200000299A1 (en) DRUGS
TR199900318T2 (en) IL-8 receptor antagonists.
EP1357909A4 (en) Il-8 receptor antagonists
BR9916159A (en) Hydroxy-diphenylurea sulphonamides as antagonists of il-8 receptors
GEP20074267B (en) Receptor nucleic acids and polypeptides
CY1106514T1 (en) IL-8 RECEPTOR ANTAGONISTS
MXPA04000707A (en) Substituted urea neuropeptide y y5 receptor antagonists.
DE60234616D1 (en) SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING ABILITY TO HISTAMINE H3 RECEPTORS
NZ514696A (en) IL-8 receptor antagonists
AP2002002605A0 (en) Il-8 receptor antagonists
WO2005000231A3 (en) Il-8 receptor antagonists
AP1548A (en) Il-8 Receptor Antagonists.
WO2001068569A3 (en) Il-8 receptor antagonists
TR199901761T2 (en) IL-8 receptor antagonists.
AP2002002606A0 (en) IL-8 receptor antagonists.
MY143477A (en) Il-8 receptor antagonists
TR200103448T2 (en) IL-8 receptor antagonists.
WO2000072800A3 (en) Il-8 receptor antagonists
WO2001068033A3 (en) Il-8 receptor antagonists
WO2001064165A3 (en) Il-8 receptor antagonists
NZ515232A (en) IL-8 receptor antagonists
WO2001068570A3 (en) Il-8 receptor antagonists
TR200100219T2 (en) IL-8 Receptor Antagonists
ECSP003527A (en) IL RECEIVER ANTAGONISTS - 8 V

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed